Related references
Note: Only part of the references are listed.CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins et al.
CANCER TREATMENT REVIEWS (2018)
Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.
Alexandra Drakaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
Joaquim Bellmunt et al.
BRITISH JOURNAL OF CANCER (2018)
Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy
Ronald De Wit et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Drug review: Pazopanib
Shingo Miyamoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitors for urothelial carcinoma
Hyung Suk Kim et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2018)
Incorporating VEGF-targeted therapy in advanced urothelial cancer
Sujata Narayanan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Evolution of ramucirumab in the treatment of cancer - A review of literature
A. Vennepureddy et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Global Burden of Urologic Cancers, 1990-2013
Geolani W. Dy et al.
EUROPEAN UROLOGY (2017)
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Family history of cancer and the risk of bladder cancer: A case-control study from Italy
Federica Turati et al.
CANCER EPIDEMIOLOGY (2017)
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
Sujata Narayanan et al.
CLINICAL GENITOURINARY CANCER (2016)
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine plus /- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
Robert J. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P. Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Contemporary Occupational Carcinogen Exposure and Bladder Cancer A Systematic Review and Meta-analysis
Marcus G. K. Cumberbatch et al.
JAMA ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Roberto Pili et al.
CLINICAL GENITOURINARY CANCER (2013)
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun V. Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
Yoo-Joung Ko et al.
LANCET ONCOLOGY (2013)
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Andrea Necchi et al.
LANCET ONCOLOGY (2012)
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2011)
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Noah M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ethnic Differences in Bladder Cancer Survival
David S. Yee et al.
UROLOGY (2011)
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
Przemyslaw Twardowski et al.
UROLOGY (2010)
Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer A Trial of the Eastern Cooperative Oncology Group
Robert Dreicer et al.
CANCER (2009)
Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker
Geraldine Pignot et al.
EUROPEAN UROLOGY (2009)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
Christopher J. Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mechanisms of disease: angiogenesis in urologic malignancies
PJS Charlesworth et al.
NATURE CLINICAL PRACTICE UROLOGY (2006)
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
CN Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer
S Bernardini et al.
JOURNAL OF UROLOGY (2001)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
CN Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
